These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25790980)

  • 1. Multiple Mechanisms Drive Resistance to ALK Inhibitors in Lung Cancer.
    Cancer Discov; 2015 May; 5(5):OF10. PubMed ID: 25790980
    [No Abstract]   [Full Text] [Related]  

  • 2. A functional landscape of resistance to ALK inhibition in lung cancer.
    Wilson FH; Johannessen CM; Piccioni F; Tamayo P; Kim JW; Van Allen EM; Corsello SM; Capelletti M; Calles A; Butaney M; Sharifnia T; Gabriel SB; Mesirov JP; Hahn WC; Engelman JA; Meyerson M; Root DE; Jänne PA; Garraway LA
    Cancer Cell; 2015 Mar; 27(3):397-408. PubMed ID: 25759024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
    Costa DB; Kobayashi S
    J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G; Tazza M; Matocci R; Chiari R; Crinò L
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
    Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
    Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
    Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
    Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 11. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
    Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.
    van der Wekken AJ; Saber A; Hiltermann TJ; Kok K; van den Berg A; Groen HJ
    Crit Rev Oncol Hematol; 2016 Apr; 100():107-16. PubMed ID: 26852079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.
    Cha YJ; Cho BC; Kim HR; Lee HJ; Shim HS
    J Thorac Oncol; 2016 May; 11(5):e55-e58. PubMed ID: 26752677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ALK inhibitor].
    Sakamoto H
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):48-50. PubMed ID: 23842228
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update of ALK inhibitors in human clinical trials.
    Chan EL; Chin CH; Lui VW
    Future Oncol; 2016 Jan; 12(1):71-81. PubMed ID: 26618223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer.
    Qi X; Ma W; Li S; Zhou C
    Lung Cancer; 2014 Aug; 85(2):335-6. PubMed ID: 24854402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.